Solera Holdings Inc. $350M Senior Notes Assigned 'BB-' Rating (Recovery Rating: 5) Jun 11

  • ID: 1814989
  • June 2011
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) June 7, 2011--Standard & Poor's Ratings Services said today it assigned its 'BB-' issue-level rating to Solera Holdings Inc.'s $350 million senior notes due 2018. The new rating is one notch below the 'BB' corporate credit rating on the company. We also assigned a '5' recovery rating to this debt, indicating our expectation of modest (10%-30%) recovery for lenders in the event of a payment default. In addition, we raised the issue rating on the company's first-lien credit facilities to 'BB+' from 'BB' as a result of a revision of the recovery rating on this debt, which we revised to '2' from '3'. The '2' recovery rating indicates substantial (70%-90%) recovery. The rating revision reflects...

Companies mentioned in this report are: Solera Holdings Inc.
Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Solera Holdings Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.